Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level
| Autor: | Duk-Soo Bae, Taejong Song, Chel Hun Choi, Chang Ohk Sung, Tae-Joong Kim, Yoo-Young Lee, Ha-Jeong Kim, Jeong-Won Lee, Byoung-Gie Kim, Min Kyu Kim, S. Huh, In-Gu Do |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
medicine.medical_specialty Pathology Cell Uterine Cervical Neoplasms Gastroenterology Disease-Free Survival Monocytes Blood cell Leukocyte Count Young Adult Antigen Antigens Neoplasm Internal medicine Biomarkers Tumor Humans Medicine Survival rate Cervix Serpins Aged Neoplasm Staging Retrospective Studies Aged 80 and over Cervical cancer business.industry Monocyte Obstetrics and Gynecology Middle Aged Prognosis medicine.disease Blood Cell Count Survival Rate stomatognathic diseases medicine.anatomical_structure Oncology Multivariate Analysis Carcinoma Squamous Cell Biomarker (medicine) Female business |
| Zdroj: | Gynecologic Oncology. 124:92-97 |
| ISSN: | 0090-8258 |
| Popis: | Objective Higher level of circulating monocyte has been reported to be related with higher cancer incidence and mortality. We investigated the role of pre-treatment circulating monocyte count for cancer specific survival in cervical squamous cell carcinoma patients comparing with pre-treatment squamous cell carcinoma-related antigen (SCC-Ag) level. Methods We retrospectively enrolled patients with squamous cell carcinoma of the cervix (FIGO stage IB to IVA) who had complete blood cell counts with differential cell count and serum SCC-Ag level within 2weeks before starting initial treatment and were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007. Results The 788 patients in our study group had a median follow-up of 53.4months and a five-year survival rate of 87.8%. The median value for pre-treatment circulating monocyte count was 349/μl (21–1463), and the median concentration of SCC-Ag was 1.6ng/ml (0.1–362.0). In multivariable analysis, the pre-treatment circulating monocyte count was an independent prognostic factor for progression-free survival and overall survival in locally advanced disease ( P =0.007 and P =0.038) but not in case of SCC-Ag for overall survival. The combined index of monocyte count and SCC-Ag level could enhance the prognostic value of SCC-Ag alone in patients with locally advanced cervical squamous cell carcinoma. Conclusions A higher pre-treatment circulating monocyte count is independently associated with poor prognosis in patients with locally advanced cervical squamous cell carcinoma. The pre-treatment circulating monocyte count may be considered as an adjunctive biomarker with SCC-Ag. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect